Caldwell Sutter Capital’s NovoCure NVCR Stock Holding History

Caldwell Sutter Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19	Closed	-$284	–	959
2023 Q4	$284	Buy	+19	New	+$254	﹤0.01%	909

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caldwell Sutter Capital's NVCR Position: Q1 2024 in Review

Caldwell Sutter Capital sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 19 shares — an estimated $284 sold.

Caldwell Sutter Capital first reported a position in NVCR in Q4 2023 and held it in 1 quarter. The position peaked at $284 in Q4 2023. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

Caldwell Sutter Capital reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
Caldwell Sutter Capital sold 19 NovoCure shares in Q1 2024, an estimated $284.
Caldwell Sutter Capital first reported a position in NovoCure in Q4 2023 and held it in 1 quarter.
Caldwell Sutter Capital's NovoCure position peaked at $284 in Q4 2023.
237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Caldwell Sutter Capital's 13F filing for Q1 2024, filed 19 Apr 2024.